Aim: This study aimed to evaluate the association between tamoxifen use and hip fractures in older women with breast cancer in Taiwan.
Introduction
With the advancement of disease screening, diagnosis, and surgical and medical treatments, the survival time of patients with breast cancer is now significantly prolonged. 1 After analyzing nationwide health insurance claims data, Liu et al. reported that the incidence of breast cancer almost doubled from 52.34 per 100 000 person-years in 1997 to 93.00 per 100 000 personyears in 2013. Even though the overall 5-year mortality rate was similar between 1997 and 2008 (4.5% vs 4.5%), the mortality rate of patients with breast cancer and comorbidities in Taiwan improved (39.1% vs 21.1%). 2 Long-term quality of life is, therefore, an important issue in patients with breast cancer, particularly older patients or those with comorbidities.
To improve the quality of life, physical activity and regular weight-bearing exercise for breast cancer survivors were suggested. 1 However, the presence of hip fractures might prevent patients from following these recommendations and could impact their quality of life. Even after aggressive treatment combined with surgical intervention, the quality of life after hip fractures remains a matter of concern. 3 In 2016, Dyer et al. concluded that only approximately half of the older patients regained their level of independence to carry out basic activities of daily living after suffering a hip fracture. 4 Interdisciplinary, comprehensive and subacute care intervention programs were introduced to improve health outcomes for older adults with hip fractures, but decreasing the risk of hip fracture in this fragile older population might be the most important issue of all. 5 The risk of hip fractures in patients with breast cancer has been discussed for decades. 6 Radiation, chemotherapy and other treatment regimens might also contribute to the risk of a hip fracture. In the 1990s, Love et al. used photon absorptiometry to report a trend toward increasing bone mineral density of the lumbar spine in postmenopausal women using tamoxifen, who also had breast cancer. 
Sampled participants
The diagnosis of sampled participants was based on the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). Female patients with breast cancer aged ≥65 years and who were newly diagnosed with a hip fracture (ICD-9-CM code 820) in claims data from 2000 to 2011 were identified for inclusion in the study. The date when a hip fracture was diagnosed was defined as the index date. Additionally, for every one patient with a hip fracture, approximately 10 female patients with breast cancer aged ≥65 years who never had a diagnosis of hip fracture were randomly selected from the same database as controls.
Comorbidities
Age and comorbidities potentially relating to hip fractures before the index date were included as follows: alcohol-related diseases, cardiovascular diseases (including coronary artery disease, heart failure, cerebrovascular disease and peripheral atherosclerosis), chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hyperlipidemia, hypertension, osteoporosis, dementia and depression. All comorbidities were also based on ICD-9-CM codes in the claims data.
Measurement of tamoxifen use and aromatase inhibitors use
Prescription history of tamoxifen and other aromatase inhibitors was included in the study. Medication use was defined as patients who had, at the minimum, a prescription for medications issued before the index date. The lack of medication use was defined as patients who never had a prescription for medications before the index date studied.
Statistical analysis
We compared distributions of the demographic status, tamoxifen use, other aromatase inhibitor use, and comorbidities between cases and controls using a χ 2 -test for categorized variables. A t-test was used to examine any differences in mean age and mean duration of exposure to tamoxifen between cases and controls. Univariable and multivariable unconditional logistic regression analyses were used to calculate the odds ratio (OR) and 95% confidence interval (CI) for the association between tamoxifen use and risk of hip fractures.
Furthermore, we analyzed the duration-dependent and dosedependent effects of tamoxifen use on the risk of hip fracture. Tamoxifen was traditionally prescribed at 20 mg per day for 5 years, and was the main adjuvant treatment for patients with estrogen receptor-positive breast cancer. Therefore, we defined those completing more than half of the treatment course, 3 years (36 months), as the major population for evaluating the risk of hip fracture among patients with breast cancer, using patients who did not use tamoxifen as references. Patients using tamoxifen for <6, 7-18 and 19-36 months were evaluated in subgroups according to the accumulating prescription dosage.
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All analyses were carried out using SAS statistical software (version 9.2; SAS Institute, Cary, NC, USA). The results were considered to be statistically significant when two-tailed P-values were < 0.05.
Results
Characteristics of the study population Table 1 shows the characteristics of the study population. We identified 762 cases with a newly diagnosed hip fracture in 2000-2011 and 7620 as controls without a hip fracture. There was a significant difference (t-test, P < 0.001) between the mean ages (80.2 AE 6.31 years) in cases with a hip fracture and the controls (74.9 AE 7.72 years). The mean duration of exposure to tamoxifen was 1.62 AE 1.95 years in cases with hip fractures and 0.73 AE 1.41 years in the controls, with statistical significance (t-test, P < 0.001). Cases with hip fractures had a higher proportion of tamoxifen use than the controls (69.4% vs 39.8%, χ 2 -test, P < 0.001). They were also more likely to have used other aromatase inhibitors (19 
Risk of hip fractures associated with tamoxifen use, aromatase inhibitor use and comorbidities
After optimizing the results of the univariable analysis mentioned above, the multivariable unconditional logistic regression model showed that compared with participants who did not use tamoxifen, the adjusted OR for hip fracture was 2.29 for those using tamoxifen (95% CI 1.92-2.72; Table 2 ).
In Risk of hip fracture associated with the cumulative duration of tamoxifen use 
Discussion
The present study showed the association between tamoxifen use and the increased risk of hip fractures in older women with breast cancer. The effect of tamoxifen on hip fracture remains a subject of debate. Because older women have a different endocrine status and are at a considerably higher risk of hip fracture than younger women, the present study focused on the association between tamoxifen use and hip fractures in older female patients with breast cancer.
In 2008, Cooke et al. hypothesized that current tamoxifen use was associated with a substantial reduction in osteoporotic fracture. That study analyzed population-based healthcare data in Manitoba, Canada, and defined the current users as those having received at least one dispensation before the occurrence of a hip fracture. Furthermore, there was no significant association of hip fractures between remote past tamoxifen use (at least one dispensation >365 days prior) or recent past tamoxifen use (dispensation between 121 and 365 days prior) compared with those who had never used tamoxifen. 12 In 2008, based on nationwide population data in Denmark, Vestergaard et al. designed a classical case-control study and showed an increased risk of hip fractures (no increased risk of forearm and vertebral fractures) in low-dose tamoxifen users. 13 Compared with these two studies, which included patients with breast cancer (<5%) and without breast cancer in all age strata, the present study focused on older women who were diagnosed with breast cancer, and showed that these patients were at an increased risk of hip fracture. Instead of using a defined daily dose, we subgrouped the tamoxifen users according to the dosage and duration of treatment received before a hip fracture occurred, and successfully showed the dose response effect of tamoxifen use on hip fracture in older women with breast cancer. The current suggested tamoxifen treatment is 20 mg per day for 5 years. 1 The present results showed that when older patients with breast cancer took tamoxifen for >3 years, the adjusted OR for hip fracture increased to 2.74 compared with that for patients who never used tamoxifen. Compared with another cohort study that used the health insurance claims data in Taiwan, and showed an inverse association between hip fracture and tamoxifen use, the use of a case-control study design decreased the risk of temporal bias. 14 The prolonged use of tamoxifen and older age of patients might be the confounding factors associated with hip fracture. However, unlike in the control group, the age of individuals with hip fracture was similar to that of tamoxifen users and non-users, as shown in Table 3 . Furthermore, the present study evaluated older women with breast cancer; however, Tzeng et al. enrolled participants across all age groups, including premenopausal and postmenopausal women.
14 Corina et al. carried out a cross-sectional study that showed the different correlations between estrogen and bone mass in premenopausal and postmenopausal women. 15 The bony effect of tamoxifen in premenopausal and postmenopausal women might also be different. In 2013, a randomized trial comprising 12 894 female patients with breast cancer worldwide suggested that continuing adjuvant tamoxifen treatment for 10 years versus stopping it after 5 years after diagnosis of estrogen receptor-positive breast cancer produces a further reduction in the recurrence and mortality of breast cancer. 11 In that study, no significant risk of increased bone fractures was identified. However, the study design was open controlled and was carried out only in patients with early breast cancer. Thus, additional studies focusing on menopausal and older women with breast cancer would be required to support this inference.
In the present pharmaco-epidemiological study, the direct biochemical mechanism between tamoxifen and the increased risk of hip fractures in older women with breast cancer cannot be identified. Categorized as a selective estrogen receptor modulator, tamoxifen might bind estrogen receptors to act as an estrogen inhibitor in some situations, and in certain target tissues and organs, but in contrast, it might simulate estrogen-like effects in other situations. To prevent recurrence of breast cancer, we make use of the anti-estrogen effect of tamoxifen. Therefore, for hip fracture risk evaluation, its estrogen-like effect on bone density might be the first that comes to mind. In 1996, Powles et al. carried out a small-scale follow-up study using dual energy X-ray absorptiometry to show the opposite effect of tamoxifen on bone mineral density in healthy premenopausal and postmenopausal women. 16 The effect of tamoxifen on bones at different sites, and on patients of different ages and different stages of disease progression remains to be elucidated. In 1992, Love et al. carried out a 2-year follow-up prospective double-blind trial to show the estrogenic bone density-increasing effect of tamoxifen on the lumbar spine in postmenopausal women with breast cancer. However, the femur bone density was not measured as part of that study. 17, 18 The benefits of selective estrogen receptor modulators, including raloxifene and tamoxifen on bone density, could have been identified in recent studies; however, evidence on its positive effect on hip fracture is still uncertain. 19, 20 The correlation between femoral bone density and the risk of fracture in older women with breast cancer requires additional assessment. 8 Assuming that tamoxifen increased the bone density of older women with breast cancer patients, its impact was another cause for concern. Compared with bisphosphonates, the beneficial effect of tamoxifen on bone density was minimal, and it might not be sufficient to reach the fracture threshold (−2.5 T score). 21, 22 Furthermore, characteristics, other than bone density, could be associated with the bone quality and health required to prevent fractures. 23 The sensitivity of some patients with estrogen receptor-negative breast cancer to tamoxifen showed at a possible complicated occult biochemical association between tamoxifen and hip fracture in patients with breast cancer. 16, 24 Muscle weakness in older women with breast cancer could be another factor associated with risk of hip fracture. Patients treated with tamoxifen were estrogen receptor-positive. Studies have reported a positive relationship between estrogen and selective estrogen receptor modulators, as well as muscle cell differentiation and function. [25] [26] [27] This association could affect the risk of hip fracture in older women with breast cancer patients treated with tamoxifen. Limitations of our study should be mentioned. Because we used data from insurance claims, information on diet, lifestyle and physical examination status was not available. For example, we could not adjust for patients' nutrition supplements, such as calcium and vitamin D, in our analysis. Furthermore, the unmatched case-control study design was adapted, because multiple variables were considered in our model even though the difference in efficiency is generally marginal between matched and unmatched models. Concerns regarding miscoding could not be completely eliminated. Patients with such diseases, but not making use of National Health Insurance Program, might not be included as cases. However, the high National Health Insurance coverage rate and high accessibility to medical care service in Taiwan make the omission negligible, particularly for patients with cancer. Tamoxifen is currently only suggested for patients with estrogen receptorpositive breast cancer, presenting an indication bias. Pathological fractures were another important concern. Chau et al. reported that for 50-75-year-old women with a history of breast cancer, 85% hip fractures were considered to be related to fragility and 15% were pathological; for those aged >80 years, 98.3% were related to fragility and only 1.7% was pathological. 28 Treatmentrelated confounding might also exist. Chang et al. reported atypical femur fractures among patients with breast cancer receiving intravenous bisphosphonate therapy. 29 We did not have access to serum examination data; for example, parathyroid hormone, 1, 25-dihydroxyvitamin D, alkaline phosphatase and calcium levels. 8 Inherently, we could not determine the clinical cancer stage for each patient in this claims dataset and this might influence the findings, as the risk of hip fractures might be different for patients with breast cancer at different disease stages. 6 Although tamoxifen prevents recurrence and reduces the mortality rate of breast cancer after prolonged use from 5 to 10 years, the present study shows the increasing hip fracture risk in older women with breast cancer with a clear dose-response effect. Furthermore, clinical physicians must co-evaluate the risk of falls and hip fracture in older women with breast cancer before initiating long-term tamoxifen treatment. Further prospective studies focusing on this fragile subgroup of patients with consideration of the different cancer stages must be carried out.
